Watson Pharmaceuticals Inc. on Monday reported results from four late stage trials of its drug candidate silodosin, saying the drug was well tolerated and reduced symptoms of prostate enlargement
Watson presented results from the studies at two American Urological Association conferences. It said the drug reduced the symptoms of prostate enlargement and increased urine flow in two late stage trials, and two safety trials showed the drug did not increase blood pressure.
The company also announced that the marketing name for silodosin will be Rapaflo.
In two pooled trials, Watson said patients who took Rapaflo experienced significant improvement compared with those who took a placebo after 12 weeks. In the third trial, patients continued taking the drug once per day for nine months, approximately 28 percent of patients suffered a drug-related side effect. None of those side effects were termed serious.
In the fourth trial, the company tested Rapaflo in combination with two common treatments for erectile dysfunction. Watson said the regimen caused no changes in blood pressure, heart rate or dizziness.
Results were presented at the New England and Mid Atlantic AUA conferences.
In morning trading, Watson shares dipped 49 cents to $28.31.
Watson presented results from the studies at two American Urological Association conferences. It said the drug reduced the symptoms of prostate enlargement and increased urine flow in two late stage trials, and two safety trials showed the drug did not increase blood pressure.
The company also announced that the marketing name for silodosin will be Rapaflo.
In two pooled trials, Watson said patients who took Rapaflo experienced significant improvement compared with those who took a placebo after 12 weeks. In the third trial, patients continued taking the drug once per day for nine months, approximately 28 percent of patients suffered a drug-related side effect. None of those side effects were termed serious.
In the fourth trial, the company tested Rapaflo in combination with two common treatments for erectile dysfunction. Watson said the regimen caused no changes in blood pressure, heart rate or dizziness.
Results were presented at the New England and Mid Atlantic AUA conferences.
In morning trading, Watson shares dipped 49 cents to $28.31.
0 comments:
Post a Comment